Healthy Clinical Trial
Official title:
Break It Up: A Study Evaluating Breaking Up Daily Sedentary Behavior in Youth
Verified date | January 4, 2021 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: Some studies have found that people can better process sugars when they take walking breaks. Studies have also found that children's attention and memory may improve after exercise. It is not known if short walking breaks have the same effects. Researchers want to study if breaking up sitting with walking for 6 days helps children s bodies use sugars and improves concentration. Objectives: To learn if breaking up sedentary (low-activity) time with short walking breaks over 6 days affects how children s bodies use sugar. To learn if breaking up sedentary time changes children s attention, memory, feelings, activity, or eating. Eligibility: Children ages 7-11 in general good health Design: Participants will be screened with: - Medical history - Physical exam - Fasting blood tests. On 2 out of 7 total study visits, participants cannot eat or drink after 10 p.m. the night before. - Full-body X-ray - EKG (Electronic signals that record heart function through stickers) - Treadmill exercise. Heart, blood pressure, and oxygen will be monitored. - Questions about the child s health, socialization, and activity, and parent s education and economic status - Picture vocabulary test - Dietician meeting (Questions about eating habits) Participants will have visits on 6 consecutive days. Over that time, they will wear 2 devices to monitor blood sugar and activity (even while at home). Participants will have 5 after-school visits. These include: - Health check - Snack plus food for the next 24 hours - Activity monitored - 3-hour sitting tests. Participants will do non-active things. Some will have 3-minute walks every 30 minutes. - Cognitive tests and questions about mood and anxiety are given on days #1 & 5. Participants will fast before the last visit in the morning. They will have: - 9 blood draws by IV catheter. Participants will drink sugar water. - Sitting test - Activity monitored - Meal (food buffet)
Status | Completed |
Enrollment | 129 |
Est. completion date | February 23, 2021 |
Est. primary completion date | June 26, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 7 Years to 11 Years |
Eligibility | - INCLUSION CRITERIA: Participants will qualify for the study if they meet the following criteria: 1. Good general health. 2. Age greater than or equal to 7 and less than 12 years. 3. Fasting plasma glucose less than 100 mg/dL 4. Body mass index (BMI) greater than or equal to the 5th percentile, as determined by the CDC age- and sex- specific growth charts. EXCLUSION CRITERIA: Participants will be excluded from the study for: 1. Significant cardiac or pulmonary disease likely to or resulting in hypoxia or decreased perfusion. 2. Evidence of impaired glucose tolerance or type 2 diabetes, including fasting plasma glucose greater than or equal to 100 mg/dL. 3. Presence of other endocrinologic disorders leading to obesity (e.g.: Cushing Syndrome). 4. Participants who have, or whose parent/guardians have, current substance abuse or a psychiatric disorder or other condition that, in the opinion of the investigators, would impede competence, compliance, or prevent the completion of the study. 5. Participants who have, or are currently receiving, anti-psychotic drugs that would affect metabolism, cognitive outcomes, and body habitus. 6. Participants receiving medical treatment other than diet for hypertension or dyslipidemia. 7. Participants with precocious puberty and/or receiving androgen and estrogen therapy. 8. Participants currently taking medications for ADHD, or any disorder or use of medications known to affect body composition or weight including but not limited to glucocorticoids or other steroid compounds. 9. Presence of pre-existing neurocognitive disabilities, or an age-adjusted score below 85 on the Picture Vocabulary Test at the screening visit. 10. Presence of food allergies, such as peanut/tree nut, dairy, soy or any other food allergy or personal dietary restrictions that would preclude participant from consuming the daily diet or the buffet. 11. Presence of significant skin disease or allergy to adhesive material prohibiting placement of a continuous glucose monitor. 12. Participants unable or unwilling to abstain from acetaminophen, ascorbic acid, or salicylic acid during study duration. 13. Participant does not speak fluent English. 14. Participant is or becomes pregnant. 15. Participant has an ambulatory impairment OPTIONAL MRS SUPPLEMENTAL ARM INCLUSION CRITERIA (a) Participants will qualify for the study if they qualify for the primary Break It Up! study. EXCLUSION CRITERIA 1. Cannot have MRI scanning. Some of the reasons a child might not be able to have MRI include: - Implanted cardiac pacemaker or defibrillator - Cochlear Implants - Ocular foreign body (e.g. metal shavings) - Embedded shrapnel fragments - Central nervous system aneurysm clips - Implanted neural stimulator - Medical infusion pumps - Any implanted device that is incompatible with MRI. 2. Is not likely to tolerate an MRI scan. Examples of medical conditions that would make it difficult to undergo MRI include severe anxiety (nervousness) or hyperactivity which make it hard for your child to lay flat for the study. 3. Requires sedation for MRI studies. 4. Has a condition that makes entry into the scanner difficult (e.g. weight over 550 lbs, claustrophobia, etc.). 5. Has severe back-pain or motion disorders that make it hard for a child to lie on his/her back within the MRI scanner and hold still for the scan. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
United States,
Belcher BR, Berrigan D, Papachristopoulou A, Brady SM, Bernstein SB, Brychta RJ, Hattenbach JD, Tigner IL Jr, Courville AB, Drinkard BE, Smith KP, Rosing DR, Wolters PL, Chen KY, Yanovski JA. Effects of Interrupting Children's Sedentary Behaviors With Activity on Metabolic Function: A Randomized Trial. J Clin Endocrinol Metab. 2015 Oct;100(10):3735-43. doi: 10.1210/jc.2015-2803. Epub 2015 Aug 27. — View Citation
Broadney MM, Belcher BR, Berrigan DA, Brychta RJ, Tigner IL Jr, Shareef F, Papachristopoulou A, Hattenbach JD, Davis EK, Brady SM, Bernstein SB, Courville AB, Drinkard BE, Smith KP, Rosing DR, Wolters PL, Chen KY, Yanovski JA. Effects of Interrupting Sedentary Behavior With Short Bouts of Moderate Physical Activity on Glucose Tolerance in Children With Overweight and Obesity: A Randomized Crossover Trial. Diabetes Care. 2018 Oct;41(10):2220-2228. doi: 10.2337/dc18-0774. Epub 2018 Aug 6. — View Citation
Dunstan DW, Kingwell BA, Larsen R, Healy GN, Cerin E, Hamilton MT, Shaw JE, Bertovic DA, Zimmet PZ, Salmon J, Owen N. Breaking up prolonged sitting reduces postprandial glucose and insulin responses. Diabetes Care. 2012 May;35(5):976-83. doi: 10.2337/dc11-1931. Epub 2012 Feb 28. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Insulin iAUC Obtained During the Oral Glucose Tolerance Test at the Final Experimental Visit. | Insulin integrated area under the curve (iAUC) as a marker of glucose metabolism on OGTT during test day #6, collected at 0, 30, 60, 90, 120, 150, and 180 minutes after oral dextrose ingestion | test day 6 | |
Secondary | Glucose iAUC Obtained During the Oral Glucose Tolerance Test on Day # 6 of Intervention. | Integrated area under the curve (iAUC) for glucose values during the oral glucose tolerance test, collected at 0, 30, 60, 90, 120, 150, and 180 minutes after oral dextrose ingestion | test day 6 | |
Secondary | C-Peptide iAUC Obtained During the Oral Glucose Tolerance Test on Day # 6 of Intervention. | Integrated area under the curve (iAUC) for C-Peptide values during the oral glucose tolerance test, collected at 0, 30, 60, 90, 120, 150, and 180 minutes after oral dextrose ingestion | test day 6 | |
Secondary | Free Fatty Acid iAUC Obtained During the Oral Glucose Tolerance Test on Day # 6 of Intervention. | Integrated area under the curve (iAUC) for Free Fatty Acid values during the oral glucose tolerance test, collected at 0, 30, 60, 90, 120, 150, and 180 minutes after oral dextrose ingestion | test day 6 | |
Secondary | Daily Physical Activity (Step Counts/Min) During Intervention. | Mean 3-dimensional activity during the 3 hours of intervention from all days (step counts per minute) | test days 1-6 | |
Secondary | Daily Physical Activity (3-dimensional Activity Counts/Day) Outside of the Intervention. | Mean total daily 3-dimensional activity counts during the 21 hours without intervention on days 1-6 (activity counts/21 hours) from triaxial write accelerometers worn at home. Note: these are not "step counts" but total 3D activity counts because motion of the wrist at times other than walking are also recorded. There is no simple way to convert these counts to step counts. | test days 1-6 | |
Secondary | Energy Intake at the Final Test Meal. | Total energy intake (kcal) during buffet meal immediately after the end of intervention | test day 6 | |
Secondary | Percentage Fat Intake at the Final Test Meal. | Percentage Energy intake from Fat during buffet meal immediately after the end of intervention | test day 6 | |
Secondary | Percentage Carbohydrate Intake at the Final Test Meal. | Percentage Energy intake from Carbohydrate during buffet meal immediately after the end of intervention | test day 6 | |
Secondary | Percentage Protein Intake at the Final Test Meal. | Percentage Energy intake from Protein during buffet meal immediately after the end of intervention | test day 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |